Predict your next investment

About IDRI

IDRI develops products that solve intractable global health challenges. Its product-based approach to fighting infectious diseases has yielded diagnostics, vaccines, and drug development strategies.

IDRI Headquarter Location

1616 Eastlake AVenue East Suite 400

Seattle, Washington, 98102,

United States

206-381-0883

Latest IDRI News

Amyris completes 1st major license for RNA COVID vaccine

Jul 3, 2021

Amyris completes 1st major license for RNA COVID vaccine In California, Amyris, Inc. signed an exclusive license with Nant Africa, LLC relating to the development and use of the RNA COVID vaccine Amyris developed in coordination with the Infectious Disease Research Institute (IDRI). Amyris’ partnership with Nant Africa is of significant value to Amyris as it provides the fastest path to market for the Amyris and IDRI RNA technology. The license and collaboration with Nant Africa is expected to generate several million dollars in near term upfront and milestone payments, and also includes long term royalties for the use of the Amyris and IDRI technology on the African continent. The license includes the funding of human clinical trials, which upon successful completion are expected to be followed by the production and scaling of the vaccine in South Africa with a target of reaching patients by the end of this year. Amyris’ partnership with Nant Africa is of significant value to Amyris as it provides the fastest path to market for the Amyris and IDRI RNA technology. Pre-clinical data has demonstrated that this RNA Vaccine technology generates comparable immunity to the currently authorized RNA vaccines against SARS-CoV-2, without the need for cold chain logistics and with a production cost that is estimated to be around 10X lower. This RNA platform is positioned to make potent, safe and durable COVID vaccines available to all people and not just wealthy countries. Amyris continues to hold options to license exclusive use of this RNA technology for selected oncology and other target therapies.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing IDRI

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned IDRI in 1 CB Insights research brief, most recently on Sep 1, 2021.

IDRI Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

IDRI Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.